4
RaQualia Pharma Inc.
4579 JT
4579 JTRaQualia Pharma Inc.
JTFIGI: BBG001JXTH14
732.00
JPY
+9.00
(+1.24%)
- Business
- RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 3 clinical trial in the United States; and grapiprant for cancer which is in phase I clinical trial in China and the United States. The company also provides veterinary products, such as grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the indication of chronic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; potassium-competitive acid blocker to treat gastro-esophageal reflux disease that has completed phase 1 clinical trial; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial; Cyclooxygenase-2 inhibitor, which is in phase I clinical trials for the indication of pain; CB2 agonist for pain; selective sodium channel blocker for pain and itch; P2X7 receptor antagonist, which is in Phase 2 clinical trials for the target indication of chronic pain; and retinoic acid receptor alpha agonist. It has a collaborative agreement with ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.